Luye Pharma’s Alzheimer’s Disease Therapy Receives Marketing Approval in UK
The Luye Pharma Group announced, has got the approval for the marketing of the Rivastigmine Multi-Day Transdermal Patch (Rivastigmine MD) has now been granted by the UK MHRA, for the treatment of the mild to moderate dementia, which has been associated with the Alzheimer’s disease, and this drug has also received the marketing approval for […]
Continue Reading